Promethera Bio, EMD Millipore to Develop Liver Cell-based Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Promethera Biosciences today announced a collaboration with EMD Millipore to develop "an improved ready-to-use microfluidic perfusion liver assay."

Promethera added that it and EMD Millipore, a division of Germany's Merck KGaA, are receiving €900,000 ($1.2 million) from the Belgian Walloon Region Biocluster and the Massachusetts Life Sciences Center to support development of the assay, which is being designed so that "more robust studies in pre-clinical toxicity and drug metabolism" can be achieved.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.